BTK Degraders and Other Targets in Mantle Cell Lymphoma
Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.
The Role of Bispecific Antibodies in Mantle Cell Lymphoma
A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.
Treating Patients With MCL Who Progress on BTK Inhibitors
Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.
CAR T-Cell Therapy in Patients With MCL: Clinical Trial and Real-World Data
A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.
Patient Profile 2: A 60-Year-Old Man With Mantle Cell Lymphoma
Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.
Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma
A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.
Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib
A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.
BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma
Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.
SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL
A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.
Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?
Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.
TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL
Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.
Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma
A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.
Overview of Mantle Cell Lymphoma and First-Line Treatment Options
Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.
Dr. Shah on Evaluating AUTO1 in Relapsed/Refractory B-Cell ALL
Dr. Shah on the Survival Analysis of Older Patients With B-Cell ALL in the ZUMA-3 Trial
Bijal D. Shah, MD, MS, discusses the survival analysis of subgroups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated in the phase 3 ZUMA-3 trial.
Clinical Pearls in the Management of Marginal Zone Lymphoma
Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.
Novel Treatment Strategies for Relapsed/Refractory MZL
A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.
Frontline Treatment Options for Marginal Zone Lymphoma
Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.
Clinical Pearls in the Management of Follicular Lymphoma
Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.
Optimizing the Sequencing of Therapy in Follicular Lymphoma
Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.
PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma
A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.
Novel Therapies and Treatment Selection in Patients With Relapsed/Refractory FL
Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.
Pathophysiology of Follicular Lymphoma and Frontline Therapy
Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.
Clinical Pearls in the Management of Mantle Cell Lymphoma
Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.
Optimizing MCL Management: Sequencing and Combination Strategies
Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.
CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma
A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Second-Line Therapy for MCL: Differentiating Available BTK Inhibitors
Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.
Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma
Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.
An Overview of Mantle Cell Lymphoma and Frontline Therapy
Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.
Dr. Shah on the FDA Approval of Brexucabtagene Autoleucel for B-Cell ALL
Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
2 Clarke Drive Cranbury, NJ 08512